Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
In the study, the researchers produced data that include pharmacokinetic
characteristics consistent with prolonged circulation and controlled
drug release with plasma concentrations remaining up to at least
100-fold higher than conventional docetaxel for more than 24 hours, as
well as up to a 10-fold increase in intratumoral drug concentrations
with prolonged and enhanced tumor growth suppression in multiple tumor
models compared with conventional docetaxel.
Moreover, initial clinical data in a heavily pretreated patient
population with 17 patients with advanced or metastatic solid tumor
cancers indicated that BIND-014 displays pharmacological characteristics
consistent with preclinical findings of differentiated pharmacokinetics
and accumulation at tumor sites with clinical effects seen at doses as
low as 20 percent of the normally prescribed docetaxel dose and in
cancers in which docetaxel has minimal activity (e.g., cervical cancer)."The
development of BIND-014 demonstrates that drug properties such as
solubility, metabolism, plasma binding, biodistribution and target
tissue accumulation will no longer be constrained to the same extent by
the drug chemical composition. It will also become the function of the
physicochemical properties of nanoparticles. This will allow for an
unprecedented ability to make better medicines for our patients as
demonstrated by our emerging clinical data," said Farokhzad.The
researchers note that while the science and technology of BIND-014
builds upon docetaxel's mechanism of action, the emerging evidence is
that BIND-014 significantly changes the biological effects of docetaxel
by virtue of fundamental changes in pharmacology including major
increases in tumor concentration.To date, the researchers note
that BIND-014 has been administered at doses of up to 75 mg/m2 and dose
escalation is ongoing. It has been well-tolerated with no new toxicities